Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Articles

Page Path
HOME > Intest Res > Volume 12(4); 2014 > Article
Original Article Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab
Nam Hee Kim, Yoon Suk Jung, Chang Mo Moon, Shin Yeong Lee, Eun Ran Kim1, Young Ho Kim1, Chang Kyun Lee2, Suck Ho Lee3, Jae Hak Kim4, Kyu Chan Huh5, Soon Man Yoon6, Hyun Joo Song7, Sun-Jin Boo7, Hyun Joo Jang8, You Sun Kim9, Kang-Moon Lee10, Jeong Eun Shin11, Dong Il Park
Intestinal Research 2014;12(4):281-286.
DOI: https://doi.org/10.5217/ir.2014.12.4.281
Published online: October 27, 2014

Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

1Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

2Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea.

3Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea.

4Department of Internal Medicine, Dongguk University College of Medicine, Goyang, Korea.

5Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea.

6Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea.

7Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea.

8Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Seoul, Korea.

9Department of Internal Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea.

10Department of Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea College of Medicine, Suwon, Korea.

11Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.

Correspondence to Dong Il Park, Department of Internal Medicine, Kangbuk Samsung Medical Center, 29 Saemunan-ro, Jongno-gu, Seoul 110-746, Korea. Tel: +82-2-2001-2059, Fax: +82-2-2001-2610, diksmc.park@samsung.com
• Received: November 7, 2013   • Accepted: March 7, 2014

© Copyright 2014. Korean Association for the Study of Intestinal Diseases. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
  • 5,175 Views
  • 56 Download
  • 20 Web of Science
  • 21 Crossref
  • Background/Aims
    Several recent studies have reported that the early use of infliximab (IFX) improves the prognosis of Crohn's disease (CD). However, no data are available from Asian populations, as the forementioned studies have all been conducted in Western countries. The aim of the current study was to evaluate the impact of early use of IFX on the prognosis of Korean patients with CD.
  • Methods
    Patients with a diagnosis of CD established between July 1987 and January 2012 were investigated in 12 university hospitals in Korea. Because insurance coverage for IFX treatment began in August 2005, patients were assigned to either of 2 groups based on diagnosis date. The first group included patients diagnosed from July 1987 to December 2005, and the second from January 2006 to January 2012. We compared the cumulative probabilities of operation and reoperation between the two groups using the Kaplan-Meier method and a log-rank test.
  • Results
    Of the 721 patients investigated, 443 (61.4%) comprized the second group. Although the cumulative probabilities of immunosuppressant (P<0.001) and IFX use (P<0.001) after diagnosis were significantly higher in the second group, there were no significant differences in cumulative probabilities of operation (P=0.905) or reoperation (P=0.418) between two groups.
  • Conclusions
    The early use of IFX did not reduce CD-related surgery requirements in Korean patients with CD. These study results suggest that the early use of IFX may have little impact on the clinical outcome of CD in Korean patients in the setting of a conventional step-up algorithm.
Crohn's disease (CD) is a chronic and relapsing inflammatory bowel disorder that can affect the entire gastrointestinal tract from the mouth to the anus. Major symptoms include abdominal pain, diarrhea, and weight loss. Additionally, CD can induce complications in the bowel such as stenosis, perforation, abscess, and fistula. Such complications may require repetitive operative procedures in some cases. However, the pathogenic mechanism of CD has not been completely elucidated. CD has been shown to be more common in developed countries and relatively rare in Korea, however, the prevalence of CD has shown recent and continuous increases in Asia. As a result, the socioeconomic burden of CD is gradually increasing.1
Step-up treatment has been the preferred method for managing CD and involves selecting medications according to severity of CD for the induction and maintenance of remission before initiating treatment with stronger medications. Thus, 5-aminosalicylic acid (5-ASA), antibiotics, and steroids are used as primary drugs. Immunosuppressive therapy with azathioprine (AZA) or 6-mercaptopurine (6-MP) is administered to patients with steroid dependency and refractoriness, followed by treatment with the biological agent infliximab (IFX) in cases that show no response to AZA or 6-MP treatment.
Several studies have reported that the early use of tumor necrosis factor-alpha (TNF-α) blockers, including IFX, decreased the need for hospitalization and surgery by inducing intestinal mucosal healing which can prevent or delay the occurrence of complications such as intestinal perforation, fistula, abscess and stenosis.2,3 Thus, a new concept of top-down treatment has emerged based on improvements in the intractable progression and prognosis of CD based on the early use of IFX. Previous studies that assessed the impact of early use of IFX on patients with CD were performed exclusively in Western countries and included relatively short follow-up periods. To date, there have been no studies that have investigated the impact of early use of IFX on Asian or Korean patients. Therefore, the aim of the current study was to identify the effects of early use of IFX on the natural progress and prognosis of CD in Korean patients through a long-term follow-up investigation. The current study hypothesized that the early administration of IFX increased dramatically after 2006, as insurance began to cover IFX treatment in patients with CD as of August 2005. Based on this assertion, the current study analyzed the impact of early use of IFX on the prognosis of Korean patients with CD. Therefore, the current study was designed to examine the effects of early administration of IFX on the prognosis of Korean patients with CD by comparing the prognosis (cumulative probabilities of operation and reoperation) between patient groups diagnosed with CD before and after 2006.
In this multi-center study, the medical records of 721 patients diagnosed with CD in 12 university hospitals from July 1987 through January 2012 were reviewed retrospectively. The authors retrieved data on follow-up duration, the classification of behavior and location according to the Montreal Classification, hospitalization and surgical history related to CD, the number of operations, and the use of drugs including steroids, immunosuppressants and IFX. CD was diagnosed according to international standards and interpreted comprehensively based on previous clinical characteristics, endoscopic findings, radiological findings, and pathologic findings.1 Upper gastrointestinal invasion was defined in patients with indications of CD based on endoscopic lesions (non-specific lesions such as esophageal or gastric ulcer) in the upper gastrointestinal tract including the esophagus, stomach and duodenum, and a bamboo joint-like appearance of the stomach characterized by swollen longitudinal folds transversed by erosive fissures or linear furrows. Perianal lesions were defined as complications including anal ulcer, fistula, and fissure caused by CD in the perianal region. Perianal lesion-related surgeries such as anal fistulectomy were excluded from CD-related bowel resection. Hospitalization history included only CD-related admissions and a family history of IBD limited to immediate family members. Smoking status was categorized into current, former, and never smokers.
Variables were presented as percentage (%) and mean±SD. Continuous variables were analyzed using the Student t-test, and categorical variables were compared using Chi-square and Fisher's exact tests. Kaplan-Meier analysis and log rank tests were used to compare the cumulative probabilities of operation and reoperation between groups diagnosed with CD before and after 2006. Statistical analyses were performed using SPSS PASW Statistics 18.0 (IBM, Armonk, NY, USA) and P-values <0.05 were considered statistically significant. Institutional review board approval for the current study was obtained from the Kangbuk Samsung Hospital.
A total of 721 patients with CD were enrolled and divided into 2 groups diagnosed with CD before 2006 (First group, n=278) and after 2006 (Second group, n=443). The number of male patients was greater in both groups, 194 (69.8%) and 322 (72.7%), respectively. Mean ages at diagnosis were 30.0 years (±12.8 years) and 28.3 years (±12.6 years), respectively, in the 2 groups. According to the Montreal classification at diagnosis, most of the patients were affected by CD in the ileocecal region. The numbers of patient cases with invasion in the perianal region were 76 (27.3%) and 129 (29.1%), respectively, in each group. Furthermore, the numbers of patient cases with invasion in the upper gastrointestinal tract were 21 (7.6%) and 65 (14.7%), respectively, in each group and were significantly higher in the second group (P=0.004). There were 129 (46.4%) and 163 (36.8%) patients, respectively, with stricturing or penetrating CD in each group. The percentage of patients with stricturing or penetrating CD was significantly lower in the second group (P=0.011) (Table 1).
Disease duration (average follow-up after diagnosis) was longer in the first group (6.1±3.3, 3.3±1.4, P<0.001). The proportion of patients who underwent CD-related operations (69 [24.8%] vs. 62 [14.0%], P<0.001) and the total number of operations (0.35±0.72 vs. 0.17±0.44, P<0.001) were significantly higher in the first group. Intestinal stenosis (23.9%, 25.4%) accounted for the largest percentage of all CD complications requiring surgical intervention, followed by fistula, and abscess. There was no difference in CD complications between the 2 groups. The numbers of patients receiving immunosuppressive therapy with AZA or 6-MP were 167 (60.1%) in the first group and 304 (68.6%) in the second group, and were significantly higher in the second group. However, no significant differences were found in the rates of steroid (182 cases [65.5%] vs. 263 cases [59.4%], P=0.101) and IFX use (68 cases [24.5%] vs. 133 cases [30.3%], P=0.105) between the 2 groups (Table 1).
Log rank tests and Kaplan-Meier analyses were conducted in order to compare the cumulative probabilities of IFX use between groups. The cumulative probabilities of IFX use were 1.1% vs. 16.8%, 4.4% vs. 26.0%, and 11.3% vs. 33.6% between the first and second groups at 1, 3, and 5 years after diagnosis. The cumulative probabilities were significantly higher in the second group (P<0.001) (Fig. 1). The cumulative probabilities of AZA use were 16.6% vs. 54.2%, 33.4% vs. 66.0%, and 42.2% vs. 73.0% between the 2 groups at 1, 3, and 5 years after diagnosis. The cumulative probabilities of immunosuppressive drugs were significantly higher in the second group (P<0.001) (Fig. 2). Conversely, the cumulative probabilities of operation were 12.6% vs. 10.2%, 13.7% vs. 13.4%, and 16.0% vs. 15.8% between the 2 groups at 1, 3, and 5 years after diagnosis. No statistically significant difference was found in the cumulative probabilities of operation between the 2 groups (P=0.905) (Fig. 3). Moreover, the cumulative probabilities of reoperation were 7.6% vs. 11.2%, 13.0% vs. 16.8%, and 38.7% vs. 25.0% between the 2 groups at 1, 3, and 5 years after the first surgery, and no statistically significant difference was found in the cumulative probabilities of reoperation between the 2 groups (P=0.418) (Fig. 4). No statistically significant difference was detected in the cumulative probabilities of operation and reoperation in a Cox-proportional hazard regression analysis conducted after adjusting for potentially confounding variables such as gender, smoking status, disease duration, the location and behavior of CD, and medication use.
In treating CD, IFX prevents TNF-α binding to the cell surface of inflammatory cells in the injured intestinal mucosa. Several multi-center, large-scale, prospective studies have proven the effectiveness of IFX in inducing and maintaining remission in patients with intestinal or fistula CD refractory to standard therapy.4,5,6,7,8 In recent years, the use of TNF-α blockers has become an important therapeutic strategy to induce and maintain remission in patients intolerant to conventional therapies. However, several recent studies have reported that the initiation of immunosuppressive or biological agents in patients with recurrent CD refractory to conventional therapeutic algorithms can result in the early development of severe CD-related complications.9,10 Therefore, an aggressive treatment approach has emerged as a therapeutic method aimed at improving the natural progression of CD by inducing rapid and consistent healing of the intestinal mucosa and preventing or delaying the occurrence of complications such as intestinal perforation, fistula, abscess, and stenosis. A number of studies have shown the effectiveness of this form of top-down treatment starting with the use of TNF-α blockers in the early period of disease to limit complications by preventing disease progression through prompt management of mucosal inflammation and minimizing the use of steroids.
A comparative study (Step-up/Top-down study) reported the usefulness of early administration of biological agents by dividing patients newly diagnosed with CD into 2 groups; those treated with conventional management and those treated with early combined use of immunosuppressive drugs (IFX, AZA).11 In the Crohn's Disease Clinical Study Evaluating Infliximab in a New Long-Term Treatment Regimen I (ACCENT I)4 and Crohn's Trial of the Fully Human Antibody Adalimumab for Remission Maintenance (CHARM) trials,12 the early administration of biological agents decreased hospital admission and operation rates attributable to the complications of CD by inducing clinical remission and mucosal healing in patients with CD.13,14
In conclusion, top-down treatment with TNF-α blockers, immunosuppressant medications, or their combination has been shown to improve the prognosis of CD. However, these previous studies were limited in their ability to sufficiently identify a long-term prognosis due to a relatively short follow-up period. Moreover, the aforementioned studies were mostly comprised of Western patients with CD such that no studies have yet analyzed Asian or Korean patients with CD.
The current study aimed to investigate changes in the long-term prognosis of patients with CD due to an increase in the early use of IFX in Korean patients with CD. This study was predicated on the hypothesis that the early administration of IFX increased dramatically after 2006 because health insurance began to cover IFX treatment in Korea as of August 2005. This long-term follow-up study compared prognosis between 2 groups newly diagnosed with CD before and after 2006. Patients diagnosed with CD after 2006 were administered IFX or AZA therapy earlier than those diagnosed with CD before 2006. However, surgical intervention for CD was neither delayed nor prevented. Consequently, we concluded that the early use of IFX had no influence in improving the prognosis of CD. Similarly, comparable results were shown in a Spanish study which determined that increased early use of IFX did not improve the prognosis of CD.15
Regarding possible explanations for the results of the current study, health insurance coverage of IFX in Korea is limited essentially to those who have experienced adverse effects or displayed refractoriness to treatment with AZA or 6-MP. To be more exact, IFX could not have been selected as the first drug to be administered to patients diagnosed with CD after 2006, and therefore these patients would have been limited to a step-up treatment algorithm. This would seem to be the primary cause of a lack of impact from the early use of IFX on the prognosis of CD. Additionally, this research was conducted as a multi-center retrospective study. An electronic medical record system was first introduced in Korean university hospitals during the years 2005-2008. Therefore, missing data on drug use, complications, operations, re-operations, and other information recorded before 2006 may have introduced biases that could have influenced the results. Furthermore, the diagnosis rate of IBD and its complications has increased with the widespread use of colonoscopy, elevated awareness of CD, and advances in radiological technology including CT enterography. Subsequently, operation and re-operation rates for complications may have increased spontaneously in patients diagnosed with CD after 2006 as compared with those diagnosed with CD before 2006. Lastly, it is already known that there are differences in the clinical and epidemiologic characteristics and genetic factors between Westerners and Asians.16 Although racial differences are anticipated to influence the effect of IFX on CD, additional studies will be required to provide further clarification.
There are some limitations associated with the current study. The prognosis of CD was based only on the cumulative probabilities of operation and reoperation. The prognostic factors may have been analyzed insufficiently, as cumulative admission rate, cumulative rates of intestinal complication incidence including stenosis, fistula, and perforation, and cumulative rate of steroid use were not examined. Furthermore, we were unable to investigate the degree of improvement in endoscopic mucosal activity and patient quality of life. Lastly, we had insufficient data on the periods of administration of other medications (ASA, steroids, and AZA/6-MP) used concurrently or prior to IFX, or the duration, dose, and efficacy of IFX use.
In conclusion, the current study demonstrated that an increase in the early use of IFX did not reduce the cumulative probabilities of operation and reoperation in Korean patients with CD. The study findings imply that the early use of IFX may not change or improve the long-term clinical outcomes of Korean patients with CD within the conventional framework of a step-up treatment algorithm. In order to further clarify the long-term effects of early use of IFX in Korean patients with CD, multi-center, large-scale, and prospective studies with long-term follow-up will need to be conducted.

Financial support: None.

Conflict of interest: None.

  • 1. Ye BD, Yang SK, Shin SJ, et al. Guidelines for the management of Crohn's disease. Intest Res 2012;10:26–66.Article
  • 2. Armuzzi A, De Pascalis B, Fedeli P, De Vincentis F, Gasbarrini A. Infliximab in Crohn's disease: early and long-term treatment. Dig Liver Dis 2008;40(Suppl 2): S271–S279.PMID: 18599000.ArticlePubMed
  • 3. Fasci Spurio F, Aratari A, Margagnoni G, Doddato MT, Papi C. Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid? J Gastrointestin Liver Dis 2012;21:67–73.PMID: 22457862.PubMed
  • 4. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541–1549.PMID: 12047962.ArticlePubMed
  • 5. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398–1405.PMID: 10228190.ArticlePubMed
  • 6. Targan SR, Hanauer SB, van Deventer SJ, et al. Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029–1035.PMID: 9321530.ArticlePubMed
  • 7. Richter JA, Bickston SJ. Infliximab use in luminal Crohn's disease. Gastroenterol Clin North Am 2006;35:775–793.PMID: 17129813.ArticlePubMed
  • 8. Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ. Maintenance infliximab does not result in increased abscess development in fistulizing Crohns disease: results from the ACCENT II study. Aliment Pharmacol Ther 2006;23:1127–1136.PMID: 16611273.ArticlePubMed
  • 9. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001;49:777–782.PMID: 11709511.ArticlePubMedPMC
  • 10. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244–250.PMID: 12131607.ArticlePubMed
  • 11. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660–667.PMID: 18295023.ArticlePubMed
  • 12. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52–65.PMID: 17241859.ArticlePubMed
  • 13. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402–413.PMID: 14762776.ArticlePubMed
  • 14. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433–442.PMID: 16500392.ArticlePubMed
  • 15. Domenech E, Zabana Y, Garcia-Planella E, et al. Clinical outcome of newly diagnosed Crohn's disease: a comparative, retrospective study before and after infliximab availability. Aliment Pharmacol Ther 2010;31:233–239.PMID: 19832727.ArticlePubMed
  • 16. Kim ES, Kim WH. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver 2010;4:1–14.PMID: 20479907.ArticlePubMedPMC
Fig. 1
Cumulative probability of infliximab (IFX) use during follow-up.
ir-12-281-g001.jpg
Fig. 2
Cumulative probability of azathioprine (AZA) use during follow-up.
ir-12-281-g002.jpg
Fig. 3
Cumulative probability of operation during follow-up.
ir-12-281-g003.jpg
Fig. 4
Cumulative probability of re-operation during follow-up.
ir-12-281-g004.jpg
Table 1
Baseline Characteristics of Patients With CD
ir-12-281-i001.jpg

Values are presented as mean&SD or n (%).

*Diagnosed with CD before December 31, 2005.

Diagnosed with CD after January 1, 2006.

UGI, Upper gastrointestinal; 5-ASA, 5-aminosalicylic acid; MTX, methotrexate; AZA, azathioprine; 6-MP, 6-mercaptopurine; IFX, Infliximab.

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Differences in the risk of clinical failure between thiopurine and methotrexate in bio-naïve patients with Crohn’s disease: a Korean nationwide population-based study
      Yu Kyung Jun, Eunjeong Ji, Hye Ran Yang, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyuk Yoon
      Therapeutic Advances in Gastroenterology.2024;[Epub]     CrossRef
    • The Potential of Molecular Remission: Tissue Neutrophil Elastase Is Better Than Histological Activity for Predicting Long-Term Relapse in Patients With Ulcerative Colitis in Endoscopic Remission
      Yu Kyung Jun, Hyeon Jeong Oh, Ji Ae Lee, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyuk Yoon
      Inflammatory Bowel Diseases.2024;[Epub]     CrossRef
    • Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving anti-TNF therapy: A systematic review and meta-analysis
      Dan Dou, Fangyi Zhang, Xin Deng, Yun Ma, Shuqing Wang, Xingyu Ji, Xihan Zhu, Dianpeng Wang, Shengsheng Zhang, Luqing Zhao
      Heliyon.2023; 9(9): e19609.     CrossRef
    • Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease
      Rasmus Goll, Øystein K. Moe, Kay-Martin Johnsen, Renate Meyer, Joachim Friestad, Mona D. Gundersen, Hege Kileng, Knut Johnsen, Jon R. Florholmen
      BMC Gastroenterology.2022;[Epub]     CrossRef
    • Editorial: does anti‐TNF “treatment persistence” always equate to “effective treatment”? Only objective disease assessments can answer the question
      Ashish Srinivasan, Daniel R. van Langenberg
      Alimentary Pharmacology & Therapeutics.2021; 54(5): 718.     CrossRef
    • Blocking tumor necrosis factor paved the way for targeted therapeutics in inflammatory diseases
      Cong-Qiu Chu
      Chinese Medical Journal.2021; 134(21): 2525.     CrossRef
    • A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD
      Kenechukwu O Chudy-Onwugaje, Kaci E Christian, Francis A Farraye, Raymond K Cross
      Inflammatory Bowel Diseases.2019; 25(5): 820.     CrossRef
    • Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report
      Samaneh Mohagheghi Darehranj, Sudabeh Alatab, Homayoon Vahedi, Anahita Sadeghi, Alireza Sima, Masoud Malekzadeh, Amir Anoshiravani, Hafez Fakheri, Nasser Ebrahimi Daryani, Abdolhamid Mousavi, Fariborz Mansour-Ghanaei, Mohammad Javad Zahedi, Reza Malekzade
      Middle East Journal of Digestive Diseases.2019; 12(1): 12.     CrossRef
    • Novel treatments for inflammatory bowel disease
      Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
      The Korean Journal of Internal Medicine.2018; 33(1): 20.     CrossRef
    • Association of Perianal Fistulas with Clinical Features and Prognosis of Crohn's Disease in Korea: Results from the CONNECT Study
      Jaeyoung Chun, Jong Pil Im, Ji Won Kim, Kook Lae Lee, Chang Hwan Choi, Hyunsoo Kim, Jae Hee Cheon, Byong Duk Ye, Young-Ho Kim, You Sun Kim, Yoon Tae Jeen, Dong Soo Han, Won Ho Kim, Joo Sung Kim
      Gut and Liver.2018; 12(5): 544.     CrossRef
    • Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients
      Jae Myung Cha, Dong Il Park, Sang Hyoung Park, Jeong Eun Shin, Wan Soo Kim, Suk-Kyun Yang
      Journal of Korean Medical Science.2017; 32(1): 85.     CrossRef
    • Fecal microbiota transplantation for refractory Crohn's disease
      Seon Ho Bak, Hyun Ho Choi, Jinhee Lee, Mi Hee Kim, Youn Hee Lee, Jin Su Kim, Young-Seok Cho
      Intestinal Research.2017; 15(2): 244.     CrossRef
    • Long-Term Outcomes of Infliximab Treatment in 582 Korean Patients with Crohn’s Disease: A Hospital-Based Cohort Study
      Sang Hyoung Park, Sung Wook Hwang, Min Seob Kwak, Wan Soo Kim, Jeong-Mi Lee, Ho-Su Lee, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Yong Sik Yoon, Chang Sik Yu, Jin-Ho Kim, Suk-Kyun Yang
      Digestive Diseases and Sciences.2016; 61(7): 2060.     CrossRef
    • Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
      Eun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, Chang Kyun Lee, Hyo Jong Kim, Kang-Moon Lee, You Sun Kim, Chang Soo Eun, Sung-Ae Jung, Suk-Kyun Yang, Jun Lee, Tae-Oh Kim, Yunho Jung, Geom Seog Seo, Soon Man Yoon
      Gut and Liver.2016;[Epub]     CrossRef
    • The Efficiency of Intravenous Iron Therapy in Korean Inflammatory Bowel Disease Patients
      Kyeong Ok Kim
      Gut and Liver.2016; 10(4): 487.     CrossRef
    • Clinical features of Crohn's disease in Korean patients residing in Busan and Gyeongnam
      Eun Ji Lee, Tae Oh Kim, Geun Am Song, Jong hun Lee, Hyung Wook Kim, Sam Ryong Jee, Seun Ja Park, Hyun Jin Kim, Jong Ha Park
      Intestinal Research.2016; 14(1): 30.     CrossRef
    • Advanced age impacts surgical characteristics and postoperative course in patients with Crohn's disease
      Stanislaus Argeny, Anton Stift, Martina Mittlböck, Amy C. Lord, Svenja Maschke, Mathias Schneeweiß, Stefan Riss
      International Journal of Surgery.2016; 33: 182.     CrossRef
    • The clinical usefulness of a web-based messaging system between patients with Crohn disease and their physicians
      Da Eun Jeong, Kyeong Ok Kim, Byung Ik Jang, Eun Young Kim, Jin Tae Jung, Seong Woo Jeon, Hyun Seok Lee, Eun Soo Kim, Kyung Sik Park, Kwang Bum Cho
      Medicine.2016; 95(26): e4028.     CrossRef
    • The clinical characteristics of patients with free perforation in Korean Crohn’s disease: results from the CONNECT study
      Young Seok Doh, You Sun Kim, Song I Bae, Jong Pil Im, Jae Hee Cheon, Byong Duk Ye, Ji Won Kim, Young Sook Park, Ji Hyun Lee, Young-Ho Kim, Joo Sung Kim, Dong Soo Han, Won Ho Kim
      BMC Gastroenterology.2015;[Epub]     CrossRef
    • Management of Anemia in Patients with Inflammatory Bowel Disease
      Kyeong Ok Kim
      The Korean Journal of Gastroenterology.2015; 65(3): 145.     CrossRef
    • Could Early Anti-Tumor Necrosis Factor Therapy Change the Prognosis of Crohn's Disease?
      Byong Duk Ye
      Intestinal Research.2014; 12(4): 263.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab
      Intest Res. 2014;12(4):281-286.   Published online October 27, 2014
      Close
    • XML DownloadXML Download
    Figure
    • 0
    • 1
    • 2
    • 3
    Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab
    Image Image Image Image
    Fig. 1 Cumulative probability of infliximab (IFX) use during follow-up.
    Fig. 2 Cumulative probability of azathioprine (AZA) use during follow-up.
    Fig. 3 Cumulative probability of operation during follow-up.
    Fig. 4 Cumulative probability of re-operation during follow-up.
    Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab

    Baseline Characteristics of Patients With CD

    Values are presented as mean&SD or n (%).

    *Diagnosed with CD before December 31, 2005.

    Diagnosed with CD after January 1, 2006.

    UGI, Upper gastrointestinal; 5-ASA, 5-aminosalicylic acid; MTX, methotrexate; AZA, azathioprine; 6-MP, 6-mercaptopurine; IFX, Infliximab.

    Table 1 Baseline Characteristics of Patients With CD

    Values are presented as mean&SD or n (%).

    *Diagnosed with CD before December 31, 2005.

    Diagnosed with CD after January 1, 2006.

    UGI, Upper gastrointestinal; 5-ASA, 5-aminosalicylic acid; MTX, methotrexate; AZA, azathioprine; 6-MP, 6-mercaptopurine; IFX, Infliximab.


    Intest Res : Intestinal Research
    Close layer
    TOP